MAP2K7 and Miyoshi myopathy: Trametinib [46], a MEK inhibitor, showed toxicity in seven of eleven MM cell lines, supporting the activation and the pro-survival role of the MAPK/ERK pathway in these MM cell lines (Figure 3B, Table S2).